| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.961 | 0.002 | 0.979 | Aldehyde oxidase inhibitor | 0.979 0.001 DBMET00312 0.739 0.006 DBMET00815 0.896 0.003 DBMET00822 0.827 0.004 DBMET00825 0.929 0.003 DBMET01627 0.896 0.003 DBMET00928 | DBMET00312 | |
| 0.707 | 0.023 | 0.8 | Caspase 9 stimulant | 0.8 0.011 DBMET00312 0.43 0.094 DBMET00815 0.653 0.029 DBMET00822 0.574 0.04 DBMET00825 0.379 0.124 DBMET01627 0.653 0.029 DBMET00928 | DBMET00312 | |
| 0.645 | 0.009 | 0.645 | Spasmolytic | 0.635 0.01 DBMET00312 0.294 0.072 DBMET00815 0.466 0.028 DBMET00822 0.587 0.014 DBMET00825 0.462 0.029 DBMET01627 0.466 0.028 DBMET00928 | ||
| 0.579 | 0.008 | 0.61 | Anticonvulsant | 0.446 0.017 DBMET00312 0.562 0.009 DBMET00822 0.522 0.011 DBMET00825 0.61 0.006 DBMET01627 0.562 0.009 DBMET00928 | DBMET01627 | |
| 0.536 | 0.004 | 0.536 | Nav1.2 sodium channel blocker | 0.459 0.005 DBMET00312 0.165 0.049 DBMET00815 0.488 0.005 DBMET00822 0.523 0.004 DBMET00825 0.264 0.02 DBMET01627 0.488 0.005 DBMET00928 | ||
| 0.531 | 0.004 | 0.532 | Nav1.3 sodium channel blocker | 0.362 0.005 DBMET00312 0.157 0.043 DBMET00815 0.37 0.005 DBMET00822 0.532 0.004 DBMET00825 0.27 0.012 DBMET01627 0.37 0.005 DBMET00928 | DBMET00825 | |
| 0.525 | 0.002 | 0.525 | Histamine N-methyltransferase inhibitor | 0.478 0.002 DBMET00312 0.248 0.004 DBMET00815 0.463 0.002 DBMET00822 0.402 0.002 DBMET00825 0.33 0.003 DBMET01627 0.463 0.002 DBMET00928 | ||
| 0.518 | 0.004 | 0.634 | NADPH oxidase inhibitor | 0.634 0.003 DBMET00312 0.235 0.024 DBMET00815 0.418 0.005 DBMET00822 0.357 0.006 DBMET00825 0.179 0.041 DBMET01627 0.418 0.005 DBMET00928 | DBMET00312 | |
| 0.515 | 0.004 | 0.532 | Alpha 2b adrenoreceptor antagonist | 0.425 0.005 DBMET00312 0.238 0.016 DBMET00815 0.328 0.008 DBMET00822 0.532 0.004 DBMET00825 0.267 0.012 DBMET01627 0.328 0.008 DBMET00928 | DBMET00825 | |
| 0.513 | 0.004 | 0.624 | Histamine H1 receptor antagonist | 0.338 0.005 DBMET00312 0.171 0.019 DBMET00815 0.275 0.008 DBMET00822 0.393 0.005 DBMET00825 0.624 0.003 DBMET01627 0.275 0.008 DBMET00928 | DBMET01627 | |
| 0.487 | 0.005 | 0.487 | 5 Hydroxytryptamine 2C antagonist | 0.289 0.009 DBMET00312 0.131 0.032 DBMET00815 0.319 0.008 DBMET00822 0.458 0.005 DBMET00825 0.191 0.018 DBMET01627 0.319 0.008 DBMET00928 | ||
| 0.482 | 0.008 | 0.523 | Cyclic AMP phosphodiesterase inhibitor | 0.523 0.005 DBMET00312 0.209 0.087 DBMET00815 0.343 0.027 DBMET00822 0.311 0.038 DBMET00825 0.267 0.056 DBMET01627 0.343 0.027 DBMET00928 | DBMET00312 | |
| 0.495 | 0.03 | 0.511 | Histamine release inhibitor | 0.511 0.025 DBMET00312 0.249 0.156 DBMET00815 0.478 0.037 DBMET00822 0.429 0.061 DBMET00825 0.379 0.086 DBMET01627 0.478 0.037 DBMET00928 | DBMET00312 | |
| 0.482 | 0.018 | 0.496 | Vasodilator, coronary | 0.496 0.016 DBMET00312 0.28 0.105 DBMET00815 0.382 0.041 DBMET00822 0.441 0.025 DBMET00825 0.337 0.062 DBMET01627 0.382 0.041 DBMET00928 | DBMET00312 | |
| 0.473 | 0.013 | 0.501 | Psychostimulant | 0.4 0.022 DBMET00312 0.189 0.086 DBMET00815 0.417 0.02 DBMET00822 0.501 0.011 DBMET00825 0.471 0.014 DBMET01627 0.417 0.02 DBMET00928 | DBMET00825 | |
| 0.458 | 0.006 | 0.458 | 5 Hydroxytryptamine 2B antagonist | 0.357 0.011 DBMET00312 0.137 0.047 DBMET00815 0.292 0.015 DBMET00822 0.378 0.009 DBMET00825 0.197 0.027 DBMET01627 0.292 0.015 DBMET00928 | ||
| 0.458 | 0.007 | 0.458 | 5 Hydroxytryptamine 2 antagonist | 0.305 0.016 DBMET00312 0.125 0.055 DBMET00815 0.274 0.019 DBMET00822 0.443 0.008 DBMET00825 0.194 0.032 DBMET01627 0.274 0.019 DBMET00928 | ||
| 0.439 | 0.004 | 0.439 | 5 Hydroxytryptamine 1F antagonist | 0.264 0.007 DBMET00312 0.085 0.04 DBMET00815 0.152 0.016 DBMET00822 0.246 0.008 DBMET00825 0.188 0.011 DBMET01627 0.152 0.016 DBMET00928 | ||
| 0.433 | 0.005 | 0.433 | Anesthetic local | 0.33 0.01 DBMET00312 0.139 0.054 DBMET00815 0.242 0.022 DBMET00822 0.359 0.008 DBMET00825 0.211 0.029 DBMET01627 0.242 0.022 DBMET00928 | ||
| 0.415 | 0.005 | 0.415 | Butyrylcholinesterase inhibitor | 0.32 0.009 DBMET00312 0.178 0.026 DBMET00815 0.254 0.014 DBMET00822 0.299 0.01 DBMET00825 0.198 0.022 DBMET01627 0.254 0.014 DBMET00928 | ||
| 0.412 | 0.003 | 0.412 | Sphingomyelinase inhibitor | 0.31 0.003 DBMET00312 0.19 0.012 DBMET00815 0.259 0.004 DBMET00822 0.364 0.003 DBMET00825 0.231 0.005 DBMET01627 0.259 0.004 DBMET00928 | ||
| 0.416 | 0.006 | 0.416 | 5 Hydroxytryptamine 2A antagonist | 0.239 0.016 DBMET00312 0.104 0.045 DBMET00815 0.232 0.016 DBMET00822 0.378 0.008 DBMET00825 0.153 0.027 DBMET01627 0.232 0.016 DBMET00928 | ||
| 0.407 | 0.004 | 0.407 | Nav1.6 sodium channel blocker | 0.345 0.005 DBMET00312 0.148 0.057 DBMET00815 0.308 0.005 DBMET00822 0.335 0.005 DBMET00825 0.203 0.018 DBMET01627 0.308 0.005 DBMET00928 | ||
| 0.409 | 0.011 | 0.409 | 5 Hydroxytryptamine antagonist | 0.212 0.031 DBMET00312 0.229 0.028 DBMET00822 0.366 0.013 DBMET00825 0.166 0.043 DBMET01627 0.229 0.028 DBMET00928 | ||
| 0.401 | 0.021 | 0.401 | Ca2+/calmodulin-dependent kinase II alpha inhibitor | 0.343 0.039 DBMET00312 0.218 0.138 DBMET00815 0.388 0.024 DBMET00822 0.322 0.05 DBMET00825 0.287 0.074 DBMET01627 0.388 0.024 DBMET00928 | ||
| 0.374 | 0.007 | 0.473 | Antihistaminic | 0.164 0.028 DBMET00312 0.08 0.077 DBMET00815 0.178 0.025 DBMET00822 0.314 0.009 DBMET00825 0.473 0.005 DBMET01627 0.178 0.025 DBMET00928 | DBMET01627 | |
| 0.364 | 0.005 | 0.441 | Dopamine D1 antagonist | 0.441 0.004 DBMET00312 0.134 0.017 DBMET00815 0.201 0.01 DBMET00822 0.289 0.006 DBMET00825 0.13 0.018 DBMET01627 0.201 0.01 DBMET00928 | DBMET00312 | |
| 0.368 | 0.011 | 0.374 | Alpha adrenoreceptor antagonist | 0.266 0.018 DBMET00312 0.099 0.057 DBMET00815 0.214 0.025 DBMET00822 0.374 0.01 DBMET00825 0.121 0.047 DBMET01627 0.214 0.025 DBMET00928 | DBMET00825 | |
| 0.364 | 0.007 | 0.423 | Histamine antagonist | 0.146 0.03 DBMET00312 0.166 0.025 DBMET00822 0.304 0.009 DBMET00825 0.423 0.005 DBMET01627 0.166 0.025 DBMET00928 | DBMET01627 | |
| 0.352 | 0.006 | 0.352 | Calcium channel blocker | 0.231 0.021 DBMET00312 0.186 0.036 DBMET00815 0.205 0.028 DBMET00822 0.273 0.013 DBMET00825 0.327 0.008 DBMET01627 0.205 0.028 DBMET00928 | ||
| 0.395 | 0.064 | 0.411 | Calpain 2 inhibitor | 0.284 0.125 DBMET00312 0.206 0.182 DBMET00815 0.364 0.08 DBMET00822 0.411 0.055 DBMET00825 0.364 0.08 DBMET00928 | DBMET00825 | |
| 0.341 | 0.012 | 0.359 | 5 Hydroxytryptamine 1E antagonist | 0.317 0.02 DBMET00312 0.256 0.069 DBMET00815 0.31 0.024 DBMET00822 0.359 0.008 DBMET00825 0.276 0.048 DBMET01627 0.31 0.024 DBMET00928 | DBMET00825 | |
| 0.329 | 0.005 | 0.335 | Alpha 2c adrenoreceptor antagonist | 0.259 0.009 DBMET00312 0.149 0.033 DBMET00815 0.211 0.016 DBMET00822 0.335 0.005 DBMET00825 0.152 0.031 DBMET01627 0.211 0.016 DBMET00928 | DBMET00825 | |
| 0.33 | 0.006 | 0.33 | Nav1.1 sodium channel blocker | 0.308 0.008 DBMET00312 0.153 0.032 DBMET00815 0.271 0.01 DBMET00822 0.306 0.008 DBMET00825 0.209 0.017 DBMET01627 0.271 0.01 DBMET00928 | ||
| 0.325 | 0.01 | 0.325 | Dopamine antagonist | 0.256 0.014 DBMET00312 0.087 0.044 DBMET00815 0.175 0.022 DBMET00822 0.279 0.013 DBMET00825 0.29 0.012 DBMET01627 0.175 0.022 DBMET00928 | ||
| 0.316 | 0.005 | 0.316 | ATPase inhibitor | 0.297 0.006 DBMET00312 0.162 0.082 DBMET00815 0.218 0.025 DBMET00822 0.301 0.006 DBMET00825 0.255 0.012 DBMET01627 0.218 0.025 DBMET00928 | ||
| 0.343 | 0.031 | 0.343 | Sigma receptor agonist | 0.28 0.043 DBMET00312 0.133 0.099 DBMET00815 0.148 0.087 DBMET00822 0.254 0.048 DBMET00825 0.248 0.049 DBMET01627 0.148 0.087 DBMET00928 | ||
| 0.304 | 0.007 | 0.304 | Dopamine D4 antagonist | 0.21 0.012 DBMET00312 0.09 0.029 DBMET00815 0.147 0.018 DBMET00822 0.204 0.012 DBMET00825 0.093 0.028 DBMET01627 0.147 0.018 DBMET00928 | ||
| 0.303 | 0.011 | 0.308 | Alpha 1 adrenoreceptor antagonist | 0.214 0.019 DBMET00312 0.084 0.051 DBMET00815 0.168 0.026 DBMET00822 0.308 0.01 DBMET00825 0.104 0.042 DBMET01627 0.168 0.026 DBMET00928 | DBMET00825 | |
| 0.292 | 0.007 | 0.298 | Alpha 2a adrenoreceptor antagonist | 0.265 0.008 DBMET00312 0.091 0.041 DBMET00815 0.192 0.015 DBMET00822 0.298 0.007 DBMET00825 0.111 0.032 DBMET01627 0.192 0.015 DBMET00928 | DBMET00825 | |
| 0.299 | 0.015 | 0.299 | Acetylcholine M1 receptor antagonist | 0.259 0.023 DBMET00312 0.13 0.095 DBMET00815 0.257 0.023 DBMET00822 0.258 0.023 DBMET00825 0.197 0.044 DBMET01627 0.257 0.023 DBMET00928 | ||
| 0.287 | 0.005 | 0.314 | Alpha 1d adrenoreceptor antagonist | 0.191 0.01 DBMET00312 0.087 0.027 DBMET00815 0.173 0.012 DBMET00822 0.314 0.005 DBMET00825 0.112 0.02 DBMET01627 0.173 0.012 DBMET00928 | DBMET00825 | |
| 0.288 | 0.008 | 0.337 | Alpha 1b adrenoreceptor antagonist | 0.218 0.013 DBMET00312 0.099 0.035 DBMET00815 0.187 0.016 DBMET00822 0.337 0.006 DBMET00825 0.121 0.029 DBMET01627 0.187 0.016 DBMET00928 | DBMET00825 | |
| 0.348 | 0.074 | 0.517 | Thyroid hormone antagonist | 0.325 0.083 DBMET00312 0.184 0.175 DBMET00822 0.201 0.161 DBMET00825 0.517 0.03 DBMET01627 0.184 0.175 DBMET00928 | DBMET01627 | |
| 0.344 | 0.071 | 0.515 | Thyroid hormone beta antagonist | 0.309 0.083 DBMET00312 0.198 0.156 DBMET00825 0.515 0.029 DBMET01627 | DBMET01627 | |
| 0.281 | 0.011 | 0.281 | Dopamine D2 antagonist | 0.217 0.015 DBMET00312 0.069 0.045 DBMET00815 0.156 0.022 DBMET00822 0.221 0.015 DBMET00825 0.28 0.011 DBMET01627 0.156 0.022 DBMET00928 | ||
| 0.273 | 0.006 | 0.297 | Protein kinase C zeta inhibitor | 0.297 0.005 DBMET00312 0.089 0.066 DBMET00815 0.287 0.005 DBMET00822 0.19 0.012 DBMET00825 0.173 0.015 DBMET01627 0.287 0.005 DBMET00928 | DBMET00312 | |
| 0.274 | 0.007 | 0.274 | 5 Hydroxytryptamine 7 antagonist | 0.132 0.02 DBMET00312 0.061 0.044 DBMET00815 0.186 0.014 DBMET00822 0.19 0.014 DBMET00825 0.133 0.02 DBMET01627 0.186 0.014 DBMET00928 | ||
| 0.295 | 0.033 | 0.299 | MAP-kinase-activated kinase 5 inhibitor | 0.266 0.05 DBMET00312 0.299 0.03 DBMET00822 0.291 0.035 DBMET00825 0.217 0.084 DBMET01627 0.299 0.03 DBMET00928 | DBMET00928 | |
| 0.297 | 0.037 | 0.343 | Ca2+/calmodulin-dependent kinase II beta inhibitor | 0.21 0.07 DBMET00312 0.343 0.025 DBMET00822 0.267 0.045 DBMET00825 0.343 0.025 DBMET00928 | DBMET00928 | |
| 0.311 | 0.052 | 0.339 | Cardiotonic | 0.262 0.075 DBMET00312 0.184 0.135 DBMET00822 0.229 0.096 DBMET00825 0.339 0.042 DBMET01627 0.184 0.135 DBMET00928 | DBMET01627 | |
| 0.279 | 0.023 | 0.375 | Ca2+/calmodulin-dependent kinase II delta inhibitor | 0.166 0.057 DBMET00312 0.375 0.008 DBMET00822 0.307 0.017 DBMET00825 0.375 0.008 DBMET00928 | DBMET00928 | |
| 0.26 | 0.005 | 0.26 | Photosensitizer | 0.239 0.007 DBMET00312 0.123 0.053 DBMET00815 0.196 0.014 DBMET00822 0.154 0.029 DBMET00825 0.152 0.03 DBMET01627 0.196 0.014 DBMET00928 | ||
| 0.338 | 0.092 | 0.382 | GABA C receptor rho-3 antagonist | 0.333 0.095 DBMET00312 0.23 0.173 DBMET00815 0.382 0.069 DBMET00822 0.349 0.086 DBMET00825 0.264 0.143 DBMET01627 0.382 0.069 DBMET00928 | DBMET00928 | |
| 0.257 | 0.012 | 0.257 | 5 Hydroxytryptamine 1 antagonist | 0.144 0.025 DBMET00312 0.112 0.033 DBMET00822 0.205 0.016 DBMET00825 0.073 0.051 DBMET01627 0.112 0.033 DBMET00928 | ||
| 0.249 | 0.008 | 0.249 | Dopamine D3 antagonist | 0.16 0.014 DBMET00312 0.074 0.035 DBMET00815 0.113 0.022 DBMET00822 0.22 0.009 DBMET00825 0.107 0.023 DBMET01627 0.113 0.022 DBMET00928 | ||
| 0.279 | 0.038 | 0.364 | Ca2+/calmodulin-dependent kinase II gamma inhibitor | 0.185 0.071 DBMET00312 0.364 0.024 DBMET00822 0.194 0.067 DBMET00825 0.364 0.024 DBMET00928 | DBMET00928 | |
| 0.288 | 0.052 | 0.354 | HERG channel blocker | 0.354 0.037 DBMET00815 0.169 0.11 DBMET00825 0.238 0.071 DBMET01627 | DBMET00815 | |
| 0.31 | 0.074 | 0.375 | Caspase 3 stimulant | 0.375 0.052 DBMET00312 0.298 0.079 DBMET00822 0.289 0.084 DBMET00825 0.298 0.079 DBMET00928 | DBMET00312 | |
| 0.248 | 0.012 | 0.265 | Alpha 1a adrenoreceptor antagonist | 0.166 0.021 DBMET00312 0.067 0.053 DBMET00815 0.124 0.028 DBMET00822 0.265 0.011 DBMET00825 0.078 0.046 DBMET01627 0.124 0.028 DBMET00928 | DBMET00825 | |
| 0.278 | 0.048 | 0.328 | Ca2+/calmodulin-dependent kinase I alpha inhibitor | 0.204 0.088 DBMET00312 0.328 0.031 DBMET00822 0.2 0.091 DBMET00825 0.328 0.031 DBMET00928 | DBMET00928 | |
| 0.241 | 0.012 | 0.241 | 5 Hydroxytryptamine 1A antagonist | 0.146 0.021 DBMET00312 0.121 0.025 DBMET00822 0.19 0.016 DBMET00825 0.072 0.045 DBMET01627 0.121 0.025 DBMET00928 | ||
| 0.231 | 0.004 | 0.231 | 5 Hydroxytryptamine 5A antagonist | 0.135 0.009 DBMET00312 0.126 0.01 DBMET00822 0.173 0.006 DBMET00825 0.114 0.013 DBMET01627 0.126 0.01 DBMET00928 | ||
| 0.25 | 0.024 | 0.349 | Antipruritic | 0.207 0.044 DBMET00312 0.251 0.024 DBMET00822 0.252 0.024 DBMET00825 0.349 0.009 DBMET01627 0.251 0.024 DBMET00928 | DBMET01627 | |
| 0.23 | 0.005 | 0.23 | Acetylcholine M4 receptor antagonist | 0.106 0.024 DBMET00312 0.09 0.037 DBMET00815 0.117 0.019 DBMET00822 0.139 0.012 DBMET00825 0.129 0.015 DBMET01627 0.117 0.019 DBMET00928 | ||
| 0.23 | 0.005 | 0.23 | Calcium channel L-type blocker | 0.148 0.01 DBMET00312 0.08 0.04 DBMET00815 0.128 0.014 DBMET00822 0.175 0.007 DBMET00825 0.165 0.008 DBMET01627 0.128 0.014 DBMET00928 | ||
| 0.241 | 0.017 | 0.722 | DNA intercalator | 0.228 0.019 DBMET00312 0.722 0.003 DBMET00815 0.126 0.054 DBMET00822 0.138 0.048 DBMET00825 0.127 0.054 DBMET01627 0.126 0.054 DBMET00928 | DBMET00815 | |
| 0.231 | 0.009 | 0.231 | Protein kinase C gamma inhibitor | 0.211 0.012 DBMET00312 0.21 0.012 DBMET00822 0.194 0.015 DBMET00825 0.177 0.02 DBMET01627 0.21 0.012 DBMET00928 | ||
| 0.241 | 0.02 | 0.245 | 5 Hydroxytryptamine 3E antagonist | 0.184 0.096 DBMET00312 0.173 0.125 DBMET00815 0.229 0.028 DBMET00822 0.245 0.018 DBMET00825 0.225 0.032 DBMET01627 0.229 0.028 DBMET00928 | DBMET00825 | |
| 0.231 | 0.012 | 0.231 | Calcium channel (voltage-sensitive) blocker | 0.134 0.043 DBMET00312 0.132 0.045 DBMET00822 0.185 0.02 DBMET00825 0.183 0.021 DBMET01627 0.132 0.045 DBMET00928 | ||
| 0.219 | 0.004 | 0.219 | 5 Hydroxytryptamine 5 antagonist | 0.129 0.01 DBMET00312 0.123 0.011 DBMET00822 0.175 0.005 DBMET00825 0.104 0.014 DBMET01627 0.123 0.011 DBMET00928 | ||
| 0.226 | 0.011 | 0.44 | Mediator release inhibitor | 0.353 0.005 DBMET00312 0.214 0.013 DBMET00822 0.191 0.016 DBMET00825 0.44 0.004 DBMET01627 0.214 0.013 DBMET00928 | DBMET01627 | |
| 0.226 | 0.014 | 0.228 | Alpha 2 adrenoreceptor antagonist | 0.181 0.021 DBMET00312 0.137 0.031 DBMET00822 0.228 0.014 DBMET00825 0.085 0.06 DBMET01627 0.137 0.031 DBMET00928 | DBMET00825 | |
| 0.218 | 0.01 | 0.36 | 5 Hydroxytryptamine uptake inhibitor | 0.106 0.024 DBMET00312 0.36 0.005 DBMET00815 0.091 0.03 DBMET00822 0.317 0.005 DBMET00825 0.117 0.021 DBMET01627 0.091 0.03 DBMET00928 | DBMET00815 | |
| 0.213 | 0.009 | 0.228 | Adenylate cyclase stimulant | 0.228 0.005 DBMET00312 0.143 0.075 DBMET00815 0.223 0.007 DBMET00822 0.227 0.006 DBMET00825 0.171 0.034 DBMET01627 0.223 0.007 DBMET00928 | DBMET00312 | |
| 0.258 | 0.055 | 0.362 | Ca2+/calmodulin-dependent protein kinase inhibitor | 0.163 0.101 DBMET00312 0.362 0.025 DBMET00822 0.276 0.05 DBMET00825 0.362 0.025 DBMET00928 | DBMET00928 | |
| 0.221 | 0.019 | 0.221 | Acetylcholine muscarinic antagonist | 0.181 0.03 DBMET00312 0.151 0.043 DBMET00822 0.175 0.032 DBMET00825 0.154 0.042 DBMET01627 0.151 0.043 DBMET00928 | ||
| 0.217 | 0.021 | 0.218 | Antiadrenergic | 0.168 0.031 DBMET00312 0.151 0.035 DBMET00822 0.218 0.021 DBMET00825 0.083 0.069 DBMET01627 0.151 0.035 DBMET00928 | DBMET00825 | |
| 0.219 | 0.023 | 0.26 | Adenylate cyclase inhibitor | 0.22 0.022 DBMET00312 0.26 0.018 DBMET00822 0.177 0.031 DBMET00825 0.098 0.086 DBMET01627 0.26 0.018 DBMET00928 | DBMET00928 | |
| 0.209 | 0.022 | 0.209 | Adrenaline antagonist | 0.161 0.032 DBMET00312 0.143 0.037 DBMET00822 0.209 0.022 DBMET00825 0.078 0.07 DBMET01627 0.143 0.037 DBMET00928 | ||
| 0.265 | 0.079 | 0.265 | Ca(v)3.3 blocker | 0.223 0.147 DBMET00825 0.223 0.147 DBMET01627 | ||
| 0.252 | 0.066 | 0.292 | Potassium channel (Voltage-sensitive) blocker | 0.292 0.052 DBMET00815 0.165 0.125 DBMET00825 0.205 0.092 DBMET01627 | DBMET00815 | |
| 0.188 | 0.007 | 0.188 | Dopamine uptake inhibitor | 0.121 0.014 DBMET00312 0.106 0.017 DBMET00822 0.184 0.007 DBMET00825 0.111 0.016 DBMET01627 0.106 0.017 DBMET00928 | ||
| 0.186 | 0.005 | 0.232 | Lanosterol 14 alpha demethylase inhibitor | 0.163 0.008 DBMET00312 0.129 0.022 DBMET00815 0.232 0.004 DBMET00822 0.173 0.006 DBMET00825 0.117 0.033 DBMET01627 0.232 0.004 DBMET00928 | DBMET00928 | |
| 0.253 | 0.077 | 0.253 | Glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase inhibitor | 0.224 0.087 DBMET00312 0.159 0.132 DBMET00815 0.22 0.089 DBMET00822 0.21 0.095 DBMET00825 0.22 0.089 DBMET00928 | ||
| 0.182 | 0.01 | 0.182 | 5 Hydroxytryptamine 1B antagonist | 0.09 0.028 DBMET00312 0.089 0.029 DBMET00822 0.144 0.013 DBMET00825 0.067 0.043 DBMET01627 0.089 0.029 DBMET00928 | ||
| 0.187 | 0.015 | 0.187 | Calcium antagonist | 0.083 0.061 DBMET00312 0.077 0.067 DBMET00822 0.091 0.055 DBMET00825 0.102 0.046 DBMET01627 0.077 0.067 DBMET00928 | ||
| 0.201 | 0.032 | 0.201 | Cholinergic antagonist | 0.158 0.048 DBMET00312 0.143 0.057 DBMET00822 0.172 0.042 DBMET00825 0.122 0.072 DBMET01627 0.143 0.057 DBMET00928 | ||
| 0.184 | 0.015 | 0.321 | Telomerase inhibitor | 0.13 0.024 DBMET00312 0.321 0.005 DBMET00815 0.111 0.029 DBMET00822 0.104 0.031 DBMET00825 0.255 0.009 DBMET01627 0.111 0.029 DBMET00928 | DBMET00815 | |
| 0.177 | 0.009 | 0.177 | Ca2+-transporting ATPase inhibitor | 0.171 0.012 DBMET00312 0.162 0.021 DBMET00815 0.177 0.008 DBMET00822 0.165 0.018 DBMET00825 0.147 0.05 DBMET01627 0.177 0.008 DBMET00928 | ||
| 0.248 | 0.081 | 0.479 | DNA damaging | 0.212 0.106 DBMET00312 0.479 0.016 DBMET00815 0.275 0.068 DBMET00822 0.223 0.098 DBMET00825 0.309 0.054 DBMET01627 0.275 0.068 DBMET00928 | DBMET00815 | |
| 0.199 | 0.033 | 0.209 | Acetylcholinesterase inhibitor | 0.209 0.03 DBMET00312 0.142 0.061 DBMET00825 | DBMET00312 | |
| 0.177 | 0.015 | 0.234 | DNA repair enzyme inhibitor | 0.18 0.014 DBMET00312 0.234 0.006 DBMET00815 0.151 0.031 DBMET00822 0.159 0.024 DBMET00825 0.117 0.079 DBMET01627 0.151 0.031 DBMET00928 | DBMET00815 | |
| 0.205 | 0.044 | 0.205 | Cholinergic | 0.191 0.05 DBMET00312 0.152 0.075 DBMET00825 | ||
| 0.167 | 0.007 | 0.219 | Histamine H2 receptor antagonist | 0.113 0.024 DBMET00312 0.081 0.064 DBMET00815 0.132 0.015 DBMET00822 0.219 0.005 DBMET00825 0.113 0.025 DBMET01627 0.132 0.015 DBMET00928 | DBMET00825 | |
| 0.225 | 0.066 | 0.357 | Amyloid beta aggregation inhibitor | 0.357 0.033 DBMET00312 0.197 0.079 DBMET00822 0.173 0.093 DBMET00825 0.197 0.079 DBMET00928 | DBMET00312 | |
| 0.165 | 0.006 | 0.165 | Acetylcholine M5 receptor antagonist | 0.115 0.014 DBMET00312 0.058 0.045 DBMET00815 0.085 0.022 DBMET00822 0.131 0.01 DBMET00825 0.083 0.023 DBMET01627 0.085 0.022 DBMET00928 | ||
| 0.195 | 0.037 | 0.27 | Toll-Like receptor 9 antagonist | 0.158 0.058 DBMET00312 0.21 0.031 DBMET00825 0.27 0.017 DBMET01627 | DBMET01627 | |
| 0.158 | 0.005 | 0.158 | 5 Hydroxytryptamine 6 antagonist | 0.08 0.023 DBMET00312 0.051 0.048 DBMET00815 0.115 0.011 DBMET00822 0.135 0.008 DBMET00825 0.111 0.012 DBMET01627 0.115 0.011 DBMET00928 | ||
| 0.186 | 0.035 | 0.186 | Acetylcholine antagonist | 0.146 0.052 DBMET00312 0.133 0.06 DBMET00822 0.16 0.045 DBMET00825 0.115 0.075 DBMET01627 0.133 0.06 DBMET00928 | ||
| 0.192 | 0.043 | 0.276 | MAO inhibitor | 0.276 0.023 DBMET00312 0.159 0.056 DBMET00822 0.149 0.061 DBMET00825 0.164 0.054 DBMET01627 0.159 0.056 DBMET00928 | DBMET00312 | |
| 0.19 | 0.048 | 0.237 | Diuretic | 0.171 0.06 DBMET00312 0.237 0.033 DBMET00822 0.185 0.051 DBMET00825 0.137 0.088 DBMET01627 0.237 0.033 DBMET00928 | DBMET00928 | |
| 0.164 | 0.023 | 0.171 | Heat shock protein 70 antagonist | 0.168 0.019 DBMET00312 0.171 0.017 DBMET00822 0.148 0.049 DBMET00825 0.132 0.112 DBMET01627 0.171 0.017 DBMET00928 | DBMET00928 | |
| 0.161 | 0.02 | 0.161 | Sphingosine 1-phosphate receptor 2 agonist | 0.138 0.034 DBMET00312 0.128 0.044 DBMET00822 0.127 0.045 DBMET00825 0.109 0.076 DBMET01627 0.128 0.044 DBMET00928 | ||
| 0.282 | 0.142 | 0.399 | 15-Lipoxygenase inhibitor | 0.399 0.075 DBMET00312 0.297 0.134 DBMET00822 0.266 0.152 DBMET00825 0.297 0.134 DBMET00928 | DBMET00312 | |
| 0.174 | 0.035 | 0.194 | Neuropeptide Y1 antagonist | 0.164 0.045 DBMET00312 0.194 0.021 DBMET00822 0.182 0.028 DBMET00825 0.14 0.081 DBMET01627 0.194 0.021 DBMET00928 | DBMET00928 | |
| 0.148 | 0.009 | 0.34 | Adrenaline uptake inhibitor | 0.103 0.018 DBMET00312 0.34 0.004 DBMET00815 0.087 0.023 DBMET00822 0.266 0.005 DBMET00825 0.095 0.02 DBMET01627 0.087 0.023 DBMET00928 | DBMET00815 | |
| 0.169 | 0.036 | 0.179 | MAP3K9 inhibitor | 0.156 0.051 DBMET00312 0.126 0.102 DBMET00815 0.179 0.027 DBMET00822 0.168 0.037 DBMET00825 0.139 0.079 DBMET01627 0.179 0.027 DBMET00928 | DBMET00928 | |
| 0.231 | 0.102 | 0.302 | 5 Hydroxytryptamine uptake stimulant | 0.207 0.139 DBMET00312 0.302 0.044 DBMET00822 0.229 0.104 DBMET00825 0.189 0.176 DBMET01627 0.302 0.044 DBMET00928 | DBMET00928 | |
| 0.183 | 0.055 | 0.183 | Cytidine deaminase inhibitor | 0.14 0.083 DBMET00822 0.154 0.073 DBMET00825 0.14 0.083 DBMET00928 | ||
| 0.164 | 0.037 | 0.269 | MAO A inhibitor | 0.269 0.018 DBMET00312 0.122 0.051 DBMET00822 0.148 0.042 DBMET00825 0.151 0.041 DBMET01627 0.122 0.051 DBMET00928 | DBMET00312 | |
| 0.234 | 0.113 | 0.269 | Insulysin inhibitor | 0.227 0.121 DBMET00312 0.269 0.08 DBMET00822 0.253 0.094 DBMET00825 0.269 0.08 DBMET00928 | DBMET00928 | |
| 0.123 | 0.003 | 0.123 | Adenylate cyclase 1 inhibitor | 0.113 0.004 DBMET00312 0.062 0.016 DBMET00815 0.109 0.004 DBMET00822 0.109 0.004 DBMET00825 0.079 0.008 DBMET01627 0.109 0.004 DBMET00928 | ||
| 0.127 | 0.007 | 0.127 | Dopamine D5 antagonist | 0.109 0.009 DBMET00312 0.072 0.014 DBMET00815 0.071 0.015 DBMET00822 0.068 0.016 DBMET00825 0.058 0.02 DBMET01627 0.071 0.015 DBMET00928 | ||
| 0.124 | 0.006 | 0.124 | Protein kinase C beta inhibitor | 0.111 0.009 DBMET00312 0.103 0.012 DBMET00822 0.104 0.012 DBMET00825 0.085 0.024 DBMET01627 0.103 0.012 DBMET00928 | ||
| 0.145 | 0.028 | 0.15 | Protein kinase C mu inhibitor | 0.109 0.049 DBMET00312 0.15 0.026 DBMET00822 0.142 0.03 DBMET00825 0.15 0.026 DBMET00928 | DBMET00928 | |
| 0.129 | 0.015 | 0.129 | 5 Hydroxytryptamine 1D antagonist | 0.058 0.051 DBMET00312 0.063 0.045 DBMET00822 0.096 0.024 DBMET00825 0.072 0.037 DBMET01627 0.063 0.045 DBMET00928 | ||
| 0.213 | 0.101 | 0.239 | Calpain inhibitor | 0.18 0.134 DBMET00312 0.239 0.075 DBMET00822 0.239 0.076 DBMET00825 0.239 0.075 DBMET00928 | DBMET00928 | |
| 0.115 | 0.004 | 0.131 | Benzodiazepine antagonist | 0.064 0.01 DBMET00312 0.053 0.021 DBMET00815 0.06 0.013 DBMET00822 0.075 0.005 DBMET00825 0.131 0.003 DBMET01627 0.06 0.013 DBMET00928 | DBMET01627 | |
| 0.122 | 0.012 | 0.122 | Protein kinase C eta inhibitor | 0.112 0.014 DBMET00312 0.114 0.014 DBMET00822 0.11 0.014 DBMET00825 0.089 0.02 DBMET01627 0.114 0.014 DBMET00928 | ||
| 0.125 | 0.019 | 0.147 | Glutamate release inhibitor | 0.13 0.017 DBMET00312 0.147 0.01 DBMET00822 0.138 0.013 DBMET00825 0.147 0.01 DBMET00928 | DBMET00928 | |
| 0.187 | 0.082 | 0.187 | Anesthetic general | 0.169 0.095 DBMET00312 0.137 0.128 DBMET00822 0.137 0.128 DBMET00928 | ||
| 0.134 | 0.03 | 0.183 | Nitric-oxide synthase inhibitor | 0.181 0.013 DBMET00822 0.183 0.013 DBMET00825 0.181 0.013 DBMET00928 | DBMET00825 | |
| 0.115 | 0.014 | 0.115 | 5 Hydroxytryptamine 3 antagonist | 0.081 0.024 DBMET00822 0.078 0.025 DBMET00825 0.081 0.024 DBMET00928 | ||
| 0.198 | 0.106 | 0.23 | Vasodilator | 0.23 0.082 DBMET00312 0.157 0.147 DBMET00825 | DBMET00312 | |
| 0.136 | 0.045 | 0.166 | Interleukin 8 antagonist | 0.127 0.053 DBMET00312 0.162 0.027 DBMET00822 0.166 0.025 DBMET00825 0.109 0.079 DBMET01627 0.162 0.027 DBMET00928 | DBMET00825 | |
| 0.104 | 0.014 | 0.114 | 5 Hydroxytryptamine 3 agonist | 0.069 0.037 DBMET00312 0.114 0.01 DBMET00822 0.086 0.023 DBMET00825 0.114 0.01 DBMET00928 | DBMET00928 | |
| 0.127 | 0.038 | 0.135 | Acetylcholine release stimulant | 0.107 0.072 DBMET00822 0.135 0.029 DBMET00825 0.101 0.086 DBMET01627 0.107 0.072 DBMET00928 | DBMET00825 | |
| 0.142 | 0.053 | 0.206 | Topoisomerase II inhibitor | 0.206 0.032 DBMET00312 0.191 0.035 DBMET00815 0.098 0.088 DBMET00822 0.098 0.088 DBMET00928 | DBMET00312 | |
| 0.173 | 0.087 | 0.186 | P-glycoprotein inhibitor | 0.169 0.091 DBMET00312 0.157 0.107 DBMET00825 0.186 0.074 DBMET01627 | DBMET01627 | |
| 0.093 | 0.008 | 0.093 | 5 Hydroxytryptamine 4 antagonist | 0.058 0.027 DBMET00312 0.089 0.01 DBMET00822 0.092 0.009 DBMET00825 0.068 0.018 DBMET01627 0.089 0.01 DBMET00928 | ||
| 0.104 | 0.02 | 0.104 | Acetylcholine M2 receptor antagonist | 0.073 0.034 DBMET00312 0.063 0.043 DBMET00822 0.075 0.033 DBMET00825 0.071 0.036 DBMET01627 0.063 0.043 DBMET00928 | ||
| 0.241 | 0.158 | 0.341 | Calcium channel activator | 0.246 0.152 DBMET00312 0.292 0.1 DBMET00822 0.341 0.056 DBMET00825 0.215 0.191 DBMET01627 0.292 0.1 DBMET00928 | DBMET00825 | |
| 0.096 | 0.016 | 0.122 | Beta 3 adrenoreceptor antagonist | 0.122 0.009 DBMET00312 0.063 0.047 DBMET00822 0.102 0.014 DBMET00825 0.066 0.04 DBMET01627 0.063 0.047 DBMET00928 | DBMET00312 | |
| 0.12 | 0.041 | 0.143 | Potassium channel (Ca-activated) activator | 0.143 0.03 DBMET00312 0.118 0.042 DBMET00822 0.12 0.041 DBMET00825 0.118 0.042 DBMET00928 | DBMET00312 | |
| 0.109 | 0.031 | 0.109 | Bromodomain-containing protein 2 inhibitor | 0.092 0.052 DBMET00825 0.083 0.069 DBMET01627 | ||
| 0.112 | 0.034 | 0.128 | Neuropeptide Y antagonist | 0.128 0.027 DBMET00822 0.105 0.037 DBMET00825 0.128 0.027 DBMET00928 | DBMET00928 | |
| 0.186 | 0.11 | 0.298 | Antiamyloidogenic | 0.298 0.052 DBMET00312 0.189 0.107 DBMET00822 0.199 0.101 DBMET00825 0.189 0.107 DBMET00928 | DBMET00312 | |
| 0.104 | 0.029 | 0.104 | Glycine receptor antagonist | 0.073 0.068 DBMET00312 0.073 0.069 DBMET00822 0.082 0.054 DBMET00825 0.075 0.066 DBMET01627 0.073 0.069 DBMET00928 | ||
| 0.129 | 0.053 | 0.129 | Calcium channel N-type blocker | 0.12 0.063 DBMET00825 0.121 0.062 DBMET01627 | ||
| 0.221 | 0.147 | 0.311 | Cholesterol antagonist | 0.311 0.084 DBMET00312 | DBMET00312 | |
| 0.092 | 0.021 | 0.112 | Phospholipase D inhibitor | 0.074 0.045 DBMET00312 0.082 0.031 DBMET00822 0.112 0.009 DBMET00825 0.082 0.031 DBMET00928 | DBMET00825 | |
| 0.141 | 0.075 | 0.216 | Protein kinase C nu inhibitor | 0.216 0.042 DBMET00822 0.124 0.088 DBMET00825 0.216 0.042 DBMET00928 | DBMET00928 | |
| 0.154 | 0.089 | 0.17 | Dual specificity phosphatase inhibitor | 0.17 0.075 DBMET00312 | DBMET00312 | |
| 0.175 | 0.111 | 0.223 | Potassium channel blocker | 0.223 0.079 DBMET01627 | DBMET01627 | |
| 0.075 | 0.011 | 0.243 | Kinesin antagonist | 0.053 0.015 DBMET00312 0.243 0.004 DBMET00815 0.138 0.005 DBMET00822 0.138 0.005 DBMET00928 | DBMET00815 | |
| 0.075 | 0.011 | 0.243 | Kinesin-like protein 1 inhibitor | 0.053 0.015 DBMET00312 0.243 0.004 DBMET00815 0.138 0.005 DBMET00822 0.138 0.005 DBMET00928 | DBMET00815 | |
| 0.108 | 0.044 | 0.132 | Alcohol dehydrogenase inhibitor | 0.132 0.028 DBMET00312 0.132 0.028 DBMET00822 0.09 0.064 DBMET00825 0.09 0.064 DBMET01627 0.132 0.028 DBMET00928 | DBMET00928 | |
| 0.082 | 0.02 | 0.082 | Sigma receptor antagonist | 0.053 0.033 DBMET00312 0.052 0.033 DBMET00825 0.054 0.032 DBMET01627 | ||
| 0.089 | 0.027 | 0.104 | Vanilloid 4 agonist | 0.076 0.049 DBMET00815 0.08 0.04 DBMET00822 0.104 0.014 DBMET00825 0.072 0.06 DBMET01627 0.08 0.04 DBMET00928 | DBMET00825 | |
| 0.218 | 0.156 | 0.234 | Vasodilator, peripheral | 0.234 0.14 DBMET00312 0.233 0.142 DBMET01627 | DBMET00312 | |
| 0.084 | 0.022 | 0.146 | NMDA 2C receptor antagonist | 0.086 0.021 DBMET00312 0.146 0.007 DBMET00822 0.065 0.038 DBMET00825 0.146 0.007 DBMET00928 | DBMET00928 | |
| 0.065 | 0.005 | 0.096 | Benzodiazepine receptor peripheral-type antagonist | 0.045 0.009 DBMET00312 0.034 0.023 DBMET00815 0.038 0.016 DBMET00822 0.041 0.012 DBMET00825 0.096 0.004 DBMET01627 0.038 0.016 DBMET00928 | DBMET01627 | |
| 0.08 | 0.02 | 0.165 | NMDA 2A receptor antagonist | 0.091 0.016 DBMET00312 0.165 0.006 DBMET00822 0.157 0.006 DBMET00825 0.165 0.006 DBMET00928 | DBMET00928 | |
| 0.099 | 0.04 | 0.106 | Acetylcholine nicotinic antagonist | 0.088 0.047 DBMET00822 0.106 0.036 DBMET00825 0.088 0.047 DBMET00928 | DBMET00825 | |
| 0.138 | 0.078 | 0.138 | Pregnane X receptor agonist | 0.137 0.081 DBMET01627 | ||
| 0.064 | 0.005 | 0.159 | ATM kinase inhibitor | 0.051 0.008 DBMET00312 0.159 0.003 DBMET00815 0.052 0.007 DBMET00822 0.055 0.006 DBMET00825 0.052 0.007 DBMET00928 | DBMET00815 | |
| 0.079 | 0.02 | 0.079 | Dopamine D4 agonist | 0.06 0.027 DBMET00822 0.072 0.022 DBMET00825 0.06 0.027 DBMET00928 | ||
| 0.139 | 0.082 | 0.17 | Sphingosine 1-phosphate receptor 5 antagonist | 0.141 0.076 DBMET00312 0.151 0.059 DBMET00822 0.122 0.121 DBMET00825 0.17 0.033 DBMET01627 0.151 0.059 DBMET00928 | DBMET01627 | |
| 0.068 | 0.011 | 0.073 | CC chemokine 4 receptor antagonist | 0.048 0.031 DBMET00822 0.064 0.013 DBMET00825 0.073 0.009 DBMET01627 0.048 0.031 DBMET00928 | DBMET01627 | |
| 0.092 | 0.036 | 0.092 | Interferon agonist | 0.072 0.066 DBMET00312 0.089 0.04 DBMET00822 0.076 0.058 DBMET01627 0.089 0.04 DBMET00928 | ||
| 0.11 | 0.055 | 0.164 | MAO B inhibitor | 0.164 0.033 DBMET00312 0.084 0.072 DBMET00822 0.084 0.072 DBMET00928 | DBMET00312 | |
| 0.084 | 0.029 | 0.084 | Bcl2 antagonist | 0.07 0.042 DBMET00312 0.068 0.044 DBMET01627 | ||
| 0.061 | 0.008 | 0.061 | Sigma 2 receptor antagonist | 0.041 0.012 DBMET00312 0.032 0.015 DBMET00822 0.039 0.013 DBMET00825 0.049 0.01 DBMET01627 0.032 0.015 DBMET00928 | ||
| 0.202 | 0.149 | 0.259 | Hypoxia-inducible factor 1 alpha inhibitor | 0.259 0.093 DBMET00312 0.226 0.123 DBMET00815 0.184 0.172 DBMET00825 | DBMET00312 | |
| 0.071 | 0.018 | 0.071 | Bcl-xL inhibitor | 0.064 0.029 DBMET00312 0.065 0.028 DBMET01627 | ||
| 0.099 | 0.047 | 0.099 | Polo-like kinase-1 inhibitor | 0.089 0.063 DBMET00312 0.087 0.068 DBMET00822 0.09 0.061 DBMET00825 0.087 0.068 DBMET00928 | ||
| 0.19 | 0.138 | 0.208 | Neuropeptide Y2 antagonist | 0.208 0.106 DBMET00822 0.208 0.106 DBMET00928 | DBMET00928 | |
| 0.069 | 0.019 | 0.079 | 5 Hydroxytryptamine 2 agonist | 0.077 0.016 DBMET00822 0.079 0.016 DBMET00825 0.047 0.042 DBMET01627 0.077 0.016 DBMET00928 | DBMET00825 | |
| 0.07 | 0.02 | 0.097 | Dopamine transporter inhibitor | 0.042 0.041 DBMET00312 0.097 0.012 DBMET00815 0.049 0.033 DBMET00822 0.093 0.013 DBMET00825 0.043 0.039 DBMET01627 0.049 0.033 DBMET00928 | DBMET00815 | |
| 0.078 | 0.03 | 0.078 | Potassium channel (ATP-sensitive) blocker | 0.074 0.034 DBMET00312 0.066 0.047 DBMET00825 0.065 0.05 DBMET01627 | ||
| 0.079 | 0.032 | 0.079 | 5 Hydroxytryptamine 3A antagonist | 0.073 0.038 DBMET00822 0.07 0.042 DBMET00825 0.073 0.038 DBMET00928 | ||
| 0.067 | 0.021 | 0.078 | Myc inhibitor | 0.054 0.039 DBMET00312 0.062 0.027 DBMET00822 0.078 0.014 DBMET00825 0.062 0.027 DBMET00928 | DBMET00825 | |
| 0.092 | 0.046 | 0.105 | Hematopoietic | 0.085 0.059 DBMET00312 0.105 0.031 DBMET00822 0.091 0.048 DBMET00825 0.081 0.071 DBMET01627 0.105 0.031 DBMET00928 | DBMET00928 | |
| 0.155 | 0.109 | 0.155 | Non-steroidal antiinflammatory agent | 0.15 0.114 DBMET00312 0.155 0.108 DBMET00822 0.148 0.117 DBMET00825 0.155 0.108 DBMET00928 | ||
| 0.055 | 0.012 | 0.055 | 5 Hydroxytryptamine 3B antagonist | 0.041 0.02 DBMET00825 | ||
| 0.054 | 0.013 | 0.069 | Histamine H1 receptor agonist | 0.059 0.009 DBMET00822 0.069 0.005 DBMET00825 0.046 0.025 DBMET01627 0.059 0.009 DBMET00928 | DBMET00825 | |
| 0.049 | 0.01 | 0.082 | Endothelial nitric-oxide synthase inhibitor | 0.075 0.005 DBMET00822 0.082 0.005 DBMET00825 0.075 0.005 DBMET00928 | DBMET00825 | |
| 0.07 | 0.031 | 0.07 | Acetylcholine M3 receptor antagonist | 0.068 0.033 DBMET00312 0.06 0.042 DBMET00825 | ||
| 0.05 | 0.014 | 0.051 | Heme oxygenase inhibitor | 0.041 0.036 DBMET00312 0.044 0.026 DBMET00815 0.051 0.012 DBMET00822 0.046 0.019 DBMET00825 0.051 0.012 DBMET00928 | DBMET00928 | |
| 0.041 | 0.005 | 0.041 | Myristoyl transferase inhibitor | 0.04 0.006 DBMET00822 0.04 0.005 DBMET00825 0.04 0.006 DBMET00928 | ||
| 0.059 | 0.023 | 0.065 | Topoisomerase II beta inhibitor | 0.065 0.019 DBMET00312 | DBMET00312 | |
| 0.066 | 0.031 | 0.066 | Potassium channel intermediate-conductance Ca-activated blocker | 0.066 0.032 DBMET00822 0.066 0.032 DBMET00928 | ||
| 0.075 | 0.04 | 0.083 | Dopamine agonist | 0.083 0.035 DBMET00312 0.063 0.05 DBMET00822 0.081 0.037 DBMET00825 0.063 0.05 DBMET00928 | DBMET00312 | |
| 0.057 | 0.022 | 0.068 | Histamine H4 receptor antagonist | 0.068 0.013 DBMET00822 0.064 0.016 DBMET00825 0.068 0.013 DBMET00928 | DBMET00928 | |
| 0.063 | 0.029 | 0.077 | Protein kinase C epsilon inhibitor | 0.077 0.02 DBMET00822 0.054 0.037 DBMET00825 0.077 0.02 DBMET00928 | DBMET00928 | |
| 0.085 | 0.051 | 0.104 | Acetylcholine nicotinic agonist | 0.104 0.035 DBMET00825 | DBMET00825 | |
| 0.102 | 0.069 | 0.16 | Topoisomerase I inhibitor | 0.16 0.038 DBMET00312 0.15 0.041 DBMET00815 0.108 0.064 DBMET01627 | DBMET00312 | |
| 0.073 | 0.04 | 0.131 | Protein kinase C alpha inhibitor | 0.131 0.013 DBMET00815 0.078 0.035 DBMET00822 0.061 0.059 DBMET00825 0.078 0.035 DBMET00928 | DBMET00815 | |
| 0.041 | 0.009 | 0.041 | Urotensin II agonist | 0.035 0.012 DBMET00312 0.032 0.014 DBMET01627 | ||
| 0.089 | 0.056 | 0.089 | Acetylcholine agonist | 0.083 0.063 DBMET00825 | ||
| 0.103 | 0.072 | 0.198 | 5 Hydroxytryptamine 3A agonist | 0.198 0.016 DBMET00822 0.138 0.042 DBMET00825 0.198 0.016 DBMET00928 | DBMET00928 | |
| 0.139 | 0.109 | 0.163 | LIM domain kinase 1 inhibitor | 0.163 0.085 DBMET00822 0.163 0.085 DBMET00928 | DBMET00928 | |
| 0.052 | 0.023 | 0.109 | NMDA receptor subunit 3B antagonist | 0.109 0.01 DBMET00312 0.062 0.018 DBMET00822 0.057 0.02 DBMET00825 0.062 0.018 DBMET00928 | DBMET00312 | |
| 0.073 | 0.045 | 0.095 | CXC chemokine receptor antagonist | 0.095 0.027 DBMET00822 0.082 0.036 DBMET01627 0.095 0.027 DBMET00928 | DBMET00928 | |
| 0.094 | 0.067 | 0.112 | Electrolyte absorption antagonist | 0.112 0.043 DBMET00822 0.092 0.071 DBMET00825 0.112 0.043 DBMET00928 | DBMET00928 | |
| 0.109 | 0.083 | 0.165 | Transcription factor STAT6 inhibitor | 0.104 0.096 DBMET00312 0.165 0.015 DBMET00822 0.112 0.076 DBMET00825 0.165 0.015 DBMET00928 | DBMET00928 | |
| 0.062 | 0.035 | 0.062 | Calcium channel T-type blocker | |||
| 0.043 | 0.017 | 0.055 | 2,3-Oxidosqualene-lanosterol cyclase inhibitor | 0.04 0.021 DBMET00312 0.055 0.009 DBMET00815 0.038 0.024 DBMET01627 | DBMET00815 | |
| 0.062 | 0.038 | 0.062 | Potassium channel (Ca-activated) blocker | |||
| 0.094 | 0.07 | 0.115 | Chemokine receptor antagonist | 0.103 0.06 DBMET00822 0.115 0.051 DBMET01627 0.103 0.06 DBMET00928 | DBMET01627 | |
| 0.035 | 0.011 | 0.035 | 5 Hydroxytryptamine 6 agonist | 0.033 0.013 DBMET00822 0.033 0.013 DBMET00928 | ||
| 0.174 | 0.151 | 0.243 | Streptokinase A inhibitor | 0.243 0.107 DBMET00312 0.171 0.154 DBMET00822 0.196 0.136 DBMET00825 0.171 0.154 DBMET00928 | DBMET00312 | |
| 0.084 | 0.061 | 0.182 | NMDA receptor antagonist | 0.126 0.033 DBMET00312 0.182 0.017 DBMET00822 0.114 0.038 DBMET00825 0.159 0.022 DBMET01627 0.182 0.017 DBMET00928 | DBMET00928 | |
| 0.078 | 0.056 | 0.078 | Cell adhesion molecule inhibitor | 0.074 0.063 DBMET00825 | ||
| 0.063 | 0.043 | 0.124 | NMDA receptor agonist | 0.124 0.012 DBMET00822 0.099 0.02 DBMET00825 0.124 0.012 DBMET00928 | DBMET00928 | |
| 0.035 | 0.015 | 0.035 | Sigma 1 receptor antagonist | 0.03 0.017 DBMET01627 | ||
| 0.056 | 0.036 | 0.056 | CC chemokine 2 receptor antagonist | 0.053 0.04 DBMET00825 | ||
| 0.064 | 0.045 | 0.069 | Interferon inducer | 0.069 0.036 DBMET00822 0.069 0.036 DBMET00928 | DBMET00928 | |
| 0.054 | 0.036 | 0.054 | Melanin-concentrating hormone receptor 1 antagonist | |||
| 0.039 | 0.021 | 0.039 | p53 inhibitor | 0.032 0.029 DBMET00822 0.032 0.03 DBMET01627 0.032 0.029 DBMET00928 | ||
| 0.08 | 0.063 | 0.082 | CC chemokine 5 receptor agonist | 0.082 0.059 DBMET00312 | DBMET00312 | |
| 0.066 | 0.049 | 0.075 | 5 Hydroxytryptamine agonist | 0.065 0.05 DBMET00822 0.075 0.044 DBMET00825 0.065 0.05 DBMET00928 | DBMET00825 | |
| 0.079 | 0.063 | 0.079 | Caspase 7 inhibitor | |||
| 0.06 | 0.045 | 0.088 | NMDA receptor glycine site agonist | 0.088 0.023 DBMET00822 0.058 0.047 DBMET00825 0.088 0.023 DBMET00928 | DBMET00928 | |
| 0.053 | 0.039 | 0.053 | Acetylcholine muscarinic agonist | |||
| 0.049 | 0.036 | 0.049 | Sodium/calcium exchanger inhibitor | |||
| 0.129 | 0.117 | 0.153 | Dual specificity phosphatase 3 inhibitor | 0.153 0.093 DBMET00312 | DBMET00312 | |
| 0.057 | 0.045 | 0.096 | Cannabinoid CB1 receptor agonist | 0.063 0.041 DBMET00822 0.057 0.045 DBMET00825 0.096 0.021 DBMET01627 0.063 0.041 DBMET00928 | DBMET01627 | |
| 0.034 | 0.022 | 0.034 | Protein kinase C beta I inhibitor | 0.033 0.023 DBMET00312 | ||
| 0.048 | 0.038 | 0.048 | Squalene epoxidase inhibitor | |||
| 0.084 | 0.075 | 0.095 | Prolactin inhibitor | 0.095 0.06 DBMET00312 | DBMET00312 | |
| 0.051 | 0.042 | 0.051 | Nicotinic alpha7 receptor agonist | |||
| 0.052 | 0.043 | 0.062 | Thromboxane synthase inhibitor | 0.053 0.041 DBMET00312 0.054 0.039 DBMET00822 0.062 0.025 DBMET00825 0.054 0.039 DBMET00928 | DBMET00825 | |
| 0.081 | 0.073 | 0.086 | NADH dehydrogenase inhibitor | 0.08 0.075 DBMET00312 0.086 0.063 DBMET00822 0.086 0.063 DBMET00928 | DBMET00928 | |
| 0.065 | 0.058 | 0.066 | Benzodiazepine agonist | 0.066 0.057 DBMET01627 | DBMET01627 | |
| 0.039 | 0.033 | 0.039 | Acetylcholine M1 receptor agonist | |||
| 0.109 | 0.104 | 0.15 | Toll-Like receptor antagonist | 0.15 0.056 DBMET01627 | DBMET01627 | |
| 0.062 | 0.056 | 0.077 | Potassium channel large-conductance Ca-activated activator | 0.077 0.037 DBMET00312 0.06 0.059 DBMET00822 0.063 0.054 DBMET00825 0.06 0.059 DBMET00928 | DBMET00312 | |
| 0.031 | 0.027 | 0.031 | Vanilloid 4 antagonist | |||
| 0.045 | 0.042 | 0.045 | Neuropeptide Y5 antagonist | |||
| 0.069 | 0.066 | 0.069 | Potassium channel (Tandem pore domain) blocker | 0.069 0.067 DBMET00822 0.069 0.067 DBMET00928 | ||
| 0.03 | 0.028 | 0.03 | Protein kinase C beta II inhibitor | 0.03 0.028 DBMET00312 | ||
| 0.114 | 0.112 | 0.117 | Mannose-6-phosphate isomerase inhibitor | 0.117 0.105 DBMET00312 | DBMET00312 | |
| 0.063 | 0.062 | 0.065 | MDM2 inhibitor | 0.065 0.054 DBMET00822 0.065 0.054 DBMET00928 | DBMET00928 | |
| 0.058 | 0.058 | 0.105 | Alpha adrenoreceptor agonist | 0.063 0.052 DBMET00822 0.105 0.026 DBMET00825 0.063 0.052 DBMET00928 | DBMET00825 | |
| 0.09 | 0.09 | 0.117 | GABA receptor agonist | 0.117 0.06 DBMET00822 0.107 0.069 DBMET01627 0.117 0.06 DBMET00928 | DBMET00928 | |
| 0.178 | 0.18 | 0.23 | Tyrosine 3 hydroxylase inhibitor | 0.21 0.118 DBMET00312 0.23 0.09 DBMET00822 0.183 0.17 DBMET00825 0.23 0.09 DBMET00928 | DBMET00928 | |
| 0.053 | 0.055 | 0.075 | Cannabinoid receptor agonist | 0.075 0.038 DBMET01627 | DBMET01627 | |
| 0.141 | 0.143 | 0.169 | Aryl hydrocarbon receptor agonist | 0.169 0.122 DBMET00822 0.169 0.122 DBMET00928 | DBMET00928 | |
| 0.091 | 0.093 | 0.136 | GABA C receptor antagonist | 0.136 0.039 DBMET00822 0.136 0.039 DBMET00928 | DBMET00928 | |
| 0.023 | 0.026 | 0.031 | Calcium-sensing receptor agonist | 0.031 0.013 DBMET00822 0.031 0.013 DBMET00928 | DBMET00928 | |
| 0.009 | 0.014 | 0.015 | Integrin beta2 antagonist | 0.015 0.007 DBMET00825 | DBMET00825 | |
| 0.049 | 0.053 | 0.08 | Alpha 1 adrenoreceptor agonist | 0.051 0.049 DBMET00822 0.08 0.023 DBMET00825 0.051 0.049 DBMET00928 | DBMET00825 | |
| 0.105 | 0.111 | 0.117 | Ribosomal protein S6 kinase inhibitor | 0.117 0.094 DBMET00822 0.117 0.094 DBMET00928 | DBMET00928 | |
| 0.025 | 0.031 | 0.031 | Estrogen-related receptor gamma antagonist | 0.031 0.014 DBMET00312 | DBMET00312 | |
| 0.029 | 0.036 | 0.054 | NMDA receptor subunit 3A antagonist | 0.054 0.018 DBMET00312 0.034 0.03 DBMET00822 0.033 0.032 DBMET00825 0.034 0.03 DBMET00928 | DBMET00312 | |
| 0.093 | 0.1 | 0.109 | Nav1.5 sodium channel blocker | 0.105 0.077 DBMET00822 0.109 0.07 DBMET00825 0.105 0.077 DBMET00928 | DBMET00825 | |
| 0.017 | 0.024 | 0.025 | Dopamine autoreceptor agonist | 0.025 0.016 DBMET00825 | DBMET00825 | |
| 0.045 | 0.053 | 0.058 | Nicotinic neuronal receptor agonist | 0.058 0.037 DBMET00825 | DBMET00825 | |
| 0.032 | 0.042 | 0.042 | Dopamine D2 agonist | 0.042 0.033 DBMET00312 | DBMET00312 | |
| 0.053 | 0.063 | 0.066 | Enoyl-[acyl-carrier-protein] reductase inhibitor | 0.066 0.033 DBMET00312 | DBMET00312 | |
| 0.024 | 0.034 | 0.028 | Potassium channel small-conductance Ca-activated activator | 0.028 0.025 DBMET00822 0.028 0.025 DBMET00928 | DBMET00928 | |
| 0.06 | 0.072 | 0.065 | Exportin-1 inhibitor | 0.065 0.056 DBMET00822 0.065 0.056 DBMET00928 | DBMET00928 | |
| 0.053 | 0.064 | 0.064 | Sphingosine 1-phosphate receptor 4 agonist | 0.058 0.056 DBMET00822 0.064 0.05 DBMET00825 0.058 0.056 DBMET00928 | DBMET00825 | |
| 0.056 | 0.068 | 0.144 | NMDA 2 receptor antagonist | 0.083 0.042 DBMET00312 0.144 0.018 DBMET00822 0.084 0.041 DBMET00825 0.144 0.018 DBMET00928 | DBMET00928 | |
| 0.135 | 0.147 | 0.171 | Catenin beta inhibitor | 0.171 0.065 DBMET00312 | DBMET00312 | |
| 0.071 | 0.083 | 0.089 | Myeloperoxidase inhibitor | 0.089 0.05 DBMET00822 0.089 0.05 DBMET00928 | DBMET00928 | |
| 0.048 | 0.061 | 0.064 | Botulinum neurotoxin type A inhibitor | 0.064 0.032 DBMET00822 0.064 0.032 DBMET00928 | DBMET00928 | |
| 0.189 | 0.202 | 0.213 | Ca2+/calmodulin-dependent kinase IV inhibitor | 0.213 0.132 DBMET00822 0.205 0.151 DBMET00825 0.213 0.132 DBMET00928 | DBMET00928 | |
| 0.031 | 0.045 | 0.038 | GABA uptake inhibitor | 0.038 0.03 DBMET00822 0.038 0.03 DBMET00928 | DBMET00928 | |
| 0.06 | 0.074 | 0.092 | Topoisomerase II alpha inhibitor | 0.092 0.045 DBMET00312 | DBMET00312 | |
| 0.129 | 0.145 | 0.162 | 3C-like protease (Human coronavirus) inhibitor | 0.162 0.084 DBMET00822 0.14 0.119 DBMET00825 0.162 0.084 DBMET00928 | DBMET00928 | |
| 0.101 | 0.118 | 0.124 | Antibacterial (Helicobacter pylori) | 0.123 0.076 DBMET00822 0.124 0.075 DBMET00825 0.123 0.076 DBMET00928 | DBMET00825 | |
| 0.065 | 0.082 | 0.119 | Estrogen receptor alpha antagonist | 0.119 0.019 DBMET00312 | DBMET00312 | |
| 0.155 | 0.174 | 0.293 | 5 Hydroxytryptamine release stimulant | 0.286 0.074 DBMET00822 0.293 0.072 DBMET00825 0.166 0.158 DBMET01627 0.286 0.074 DBMET00928 | DBMET00825 | |
| 0.171 | 0.192 | 0.217 | Gastrin inhibitor | 0.217 0.123 DBMET00825 | DBMET00825 | |
| 0.024 | 0.046 | 0.051 | Phosphoglycerate kinase inhibitor | 0.051 0.014 DBMET00822 0.051 0.014 DBMET00928 | DBMET00928 | |
| 0.037 | 0.06 | 0.05 | Potassium channel (Inward rectifier) blocker | 0.05 0.034 DBMET01627 | DBMET01627 | |
| 0.091 | 0.115 | 0.132 | Aldehyde dehydrogenase inhibitor | 0.109 0.084 DBMET00312 0.132 0.06 DBMET00822 0.1 0.097 DBMET00825 0.132 0.06 DBMET00928 | DBMET00928 | |
| 0.08 | 0.105 | 0.119 | Carbonic anhydrase XV inhibitor | 0.114 0.051 DBMET00312 0.119 0.047 DBMET00822 0.119 0.047 DBMET00928 | DBMET00928 | |
| 0.03 | 0.056 | 0.047 | Neurokinin 2 agonist | 0.047 0.022 DBMET00822 0.047 0.022 DBMET00928 | DBMET00928 | |
| 0.085 | 0.111 | 0.118 | Cholesterol synthesis inhibitor | 0.118 0.067 DBMET00312 | DBMET00312 | |
| 0.017 | 0.044 | 0.022 | ICAM 1 antagonist | 0.022 0.017 DBMET00825 | DBMET00825 | |
| 0.019 | 0.046 | 0.028 | LFA antagonist | 0.027 0.021 DBMET00822 0.028 0.018 DBMET00825 0.027 0.021 DBMET00928 | DBMET00825 | |
| 0.038 | 0.066 | 0.054 | Histamine agonist | 0.047 0.046 DBMET00822 0.054 0.034 DBMET00825 0.047 0.046 DBMET00928 | DBMET00825 | |
| 0.055 | 0.083 | 0.064 | Calcium channel P-type blocker | 0.064 0.042 DBMET01627 | DBMET01627 | |
| 0.083 | 0.111 | 0.099 | MAP kinase 13 inhibitor | 0.099 0.083 DBMET00822 0.099 0.083 DBMET00928 | DBMET00928 | |
| 0.128 | 0.159 | 0.162 | Succinate dehydrogenase inhibitor | 0.162 0.091 DBMET00822 0.162 0.091 DBMET00928 | DBMET00928 | |
| 0.053 | 0.084 | 0.06 | Kallikrein 7 inhibitor | 0.06 0.056 DBMET00825 | DBMET00825 | |
| 0.049 | 0.081 | 0.072 | Corticotropin releasing factor 2 receptor antagonist | 0.072 0.025 DBMET00822 0.072 0.025 DBMET00928 | DBMET00928 | |
| 0.098 | 0.13 | 0.293 | Interleukin 1 antagonist | 0.293 0.012 DBMET01627 | DBMET01627 | |
| 0.023 | 0.057 | 0.036 | CC chemokine 3 receptor antagonist | 0.036 0.034 DBMET00815 | DBMET00815 | |
| 0.055 | 0.089 | 0.077 | CYP2A6 inhibitor | 0.077 0.051 DBMET00822 0.077 0.051 DBMET00928 | DBMET00928 | |
| 0.028 | 0.064 | 0.04 | AMPA 4 receptor antagonist | 0.04 0.026 DBMET00822 0.04 0.026 DBMET00928 | DBMET00928 | |
| 0.071 | 0.107 | 0.086 | Estrogen-related receptor beta agonist | 0.086 0.049 DBMET00312 | DBMET00312 | |
| 0.041 | 0.077 | 0.069 | Protein kinase C iota inhibitor | 0.069 0.033 DBMET00822 0.069 0.033 DBMET00928 | DBMET00928 | |
| 0.17 | 0.207 | 0.331 | Beta lactamase inhibitor | 0.331 0.122 DBMET01627 | DBMET01627 | |
| 0.131 | 0.169 | 0.163 | Neurotrophic factor enhancer | 0.163 0.119 DBMET00312 0.149 0.14 DBMET00825 | DBMET00312 | |
| 0.094 | 0.132 | 0.134 | CDC-like kinase 1 inhibitor | 0.134 0.082 DBMET00312 0.121 0.094 DBMET00822 0.121 0.094 DBMET00928 | DBMET00312 | |
| 0.036 | 0.074 | 0.056 | Glutamate (mGluR1) antagonist | 0.056 0.042 DBMET00822 0.056 0.042 DBMET00928 | DBMET00928 | |
| 0.109 | 0.151 | 0.141 | GABA C receptor rho-2 antagonist | 0.141 0.086 DBMET00825 | DBMET00825 | |
| 0.051 | 0.093 | 0.066 | Histone deacetylase SIRT3 inhibitor | 0.066 0.033 DBMET00822 0.066 0.034 DBMET00825 0.066 0.033 DBMET00928 | DBMET00928 | |
| 0.015 | 0.061 | 0.029 | HCV NS5B polymerase inhibitor | 0.029 0.024 DBMET00312 | DBMET00312 | |
| 0.028 | 0.075 | 0.036 | 5 Hydroxytryptamine 2B agonist | 0.036 0.033 DBMET00822 0.036 0.033 DBMET00928 | DBMET00928 | |
| 0.06 | 0.108 | 0.087 | Viral attachment inhibitor | 0.087 0.037 DBMET01627 | DBMET01627 | |
| 0.17 | 0.219 | 0.209 | Antithrombotic | 0.209 0.167 DBMET00822 0.209 0.167 DBMET00928 | DBMET00928 | |
| 0.053 | 0.102 | 0.098 | GABA aminotransferase inhibitor | 0.098 0.028 DBMET00822 0.098 0.028 DBMET00928 | DBMET00928 | |
| 0.051 | 0.1 | 0.075 | CC chemokine receptor antagonist | 0.075 0.056 DBMET01627 | DBMET01627 | |
| 0.125 | 0.178 | 0.179 | Neurotensin receptor agonist | 0.139 0.132 DBMET00312 0.179 0.05 DBMET00822 0.152 0.096 DBMET00825 0.179 0.05 DBMET00928 | DBMET00928 | |
| 0.033 | 0.087 | 0.047 | Potassium channel (ATP-sensitive) activator | 0.047 0.036 DBMET01627 | DBMET01627 | |
| 0.035 | 0.09 | 0.049 | Potassium channel (Inward rectifier) activator | 0.049 0.038 DBMET01627 | DBMET01627 | |
| 0.059 | 0.117 | 0.096 | GABA B receptor agonist | 0.096 0.02 DBMET00822 0.096 0.02 DBMET00928 | DBMET00928 | |
| 0.042 | 0.1 | 0.063 | Beta adrenoreceptor antagonist | 0.063 0.051 DBMET00312 | DBMET00312 | |
| 0.06 | 0.118 | 0.09 | Protein kinase C delta inhibitor | 0.09 0.062 DBMET00822 0.09 0.062 DBMET00928 | DBMET00928 | |
| 0.052 | 0.113 | 0.133 | Protein kinase A inhibitor | 0.133 0.029 DBMET00822 0.078 0.062 DBMET00825 0.133 0.029 DBMET00928 | DBMET00928 | |
| 0.15 | 0.212 | 0.178 | Nitric-oxide synthase stimulant | 0.178 0.132 DBMET00822 0.178 0.132 DBMET00928 | DBMET00928 | |
| 0.215 | 0.276 | 0.251 | MAP kinase 1 inhibitor | 0.251 0.231 DBMET00825 | DBMET00825 | |
| 0.058 | 0.121 | 0.101 | Dual specificity tyrosine-phosphorylation regulated kinase 2 inhibitor | 0.081 0.061 DBMET00312 0.101 0.038 DBMET00822 0.101 0.038 DBMET00928 | DBMET00928 | |
| 0.016 | 0.08 | 0.029 | Estradiol 17 beta-dehydrogenase 3 inhibitor | 0.029 0.027 DBMET00312 | DBMET00312 | |
| 0.021 | 0.086 | 0.037 | Estrogen-related receptor beta antagonist | 0.037 0.014 DBMET00312 | DBMET00312 | |
| 0.013 | 0.079 | 0.057 | Estradiol 17 beta-dehydrogenase 2 inhibitor | 0.057 0.013 DBMET00312 | DBMET00312 | |
| 0.098 | 0.164 | 0.133 | Sphingosine 1-phosphate receptor 2 antagonist | 0.114 0.113 DBMET00825 0.133 0.068 DBMET01627 | DBMET01627 | |
| 0.018 | 0.085 | 0.054 | Estradiol 17 beta-dehydrogenase inhibitor | 0.054 0.023 DBMET00312 | DBMET00312 | |
| 0.096 | 0.165 | 0.122 | Hexokinase inhibitor | 0.122 0.115 DBMET00312 | DBMET00312 | |
| 0.186 | 0.255 | 0.322 | Analgesic | 0.276 0.161 DBMET00815 0.322 0.125 DBMET00825 | DBMET00825 | |
| 0.114 | 0.184 | 0.145 | Insulin sensitizer | 0.145 0.14 DBMET00822 0.145 0.14 DBMET00928 | DBMET00928 | |
| 0.071 | 0.143 | 0.136 | Nav1.4 sodium channel blocker | 0.136 0.04 DBMET00822 0.136 0.04 DBMET00928 | DBMET00928 | |
| 0.02 | 0.094 | 0.042 | Dopamine D5 agonist | 0.042 0.025 DBMET00822 0.042 0.025 DBMET00928 | DBMET00928 | |
| 0.054 | 0.129 | 0.092 | Inducible nitric-oxide synthase inhibitor | 0.092 0.045 DBMET00822 0.091 0.046 DBMET00825 0.092 0.045 DBMET00928 | DBMET00928 | |
| 0.019 | 0.096 | 0.054 | Chemokine receptor agonist | 0.054 0.032 DBMET00822 0.054 0.032 DBMET00928 | DBMET00928 | |
| 0.008 | 0.087 | 0.03 | CXC chemokine receptor agonist | 0.03 0.028 DBMET00822 0.03 0.028 DBMET00928 | DBMET00928 | |
| 0.153 | 0.233 | 0.255 | Transcription factor STAT inhibitor | 0.255 0.084 DBMET00822 0.255 0.084 DBMET00928 | DBMET00928 | |
| 0.078 | 0.159 | 0.204 | Estrogen antagonist | 0.204 0.012 DBMET00312 0.103 0.091 DBMET00815 | DBMET00312 | |
| 0.028 | 0.109 | 0.048 | Carnitine palmitoyltransferase 1B inhibitor | 0.048 0.032 DBMET01627 | DBMET01627 | |
| 0.03 | 0.112 | 0.058 | 3(or 17)beta-hydroxysteroid dehydrogenase inhibitor | 0.058 0.032 DBMET00312 | DBMET00312 | |
| 0.03 | 0.113 | 0.07 | CXC chemokine 4 receptor antagonist | 0.07 0.036 DBMET00822 0.07 0.036 DBMET00928 | DBMET00928 | |
| 0.057 | 0.141 | 0.098 | Creatine kinase inhibitor | 0.098 0.061 DBMET00312 0.083 0.081 DBMET00822 0.083 0.081 DBMET00928 | DBMET00312 | |
| 0.023 | 0.109 | 0.06 | CC chemokine 5 receptor antagonist | 0.06 0.026 DBMET01627 | DBMET01627 | |
| 0.03 | 0.118 | 0.046 | Dopamine beta hydroxylase inhibitor | 0.046 0.04 DBMET00822 0.046 0.04 DBMET00928 | DBMET00928 | |
| 0.113 | 0.207 | 0.138 | Phospholipase C inhibitor | 0.138 0.132 DBMET00822 0.138 0.132 DBMET00928 | DBMET00928 | |
| 0.203 | 0.302 | 0.3 | 5 Hydroxytryptamine release inhibitor | 0.3 0.165 DBMET00822 0.3 0.165 DBMET00928 | DBMET00928 | |
| 0.226 | 0.329 | 0.321 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | 0.321 0.186 DBMET00825 | DBMET00825 | |
| 0.059 | 0.162 | 0.095 | Carbonic anhydrase III inhibitor | 0.095 0.068 DBMET00312 | DBMET00312 | |
| 0.031 | 0.137 | 0.128 | Leukotriene synthesis inhibitor | 0.128 0.014 DBMET01627 | DBMET01627 | |
| 0.032 | 0.14 | 0.179 | Check point kinase 1 inhibitor | 0.179 0.011 DBMET00815 | DBMET00815 | |
| 0.069 | 0.177 | 0.14 | Lipid peroxidase inhibitor | 0.14 0.075 DBMET00312 | DBMET00312 | |
| 0.06 | 0.171 | 0.13 | Glutamate receptor antagonist | 0.13 0.065 DBMET00822 0.13 0.065 DBMET00928 | DBMET00928 | |
| 0.185 | 0.297 | 0.278 | Apoptosis agonist | 0.278 0.188 DBMET00312 | DBMET00312 | |
| 0.004 | 0.116 | 0.071 | Estrogen receptor alpha agonist | 0.071 0.013 DBMET00312 | DBMET00312 | |
| 0.134 | 0.247 | 0.189 | Transcription factor NF kappa B inhibitor | 0.189 0.181 DBMET00312 | DBMET00312 | |
| 0.025 | 0.14 | 0.054 | GABA B receptor antagonist | 0.054 0.016 DBMET00822 0.054 0.016 DBMET00928 | DBMET00928 | |
| 0.053 | 0.174 | 0.103 | Chelator | 0.103 0.073 DBMET00312 | DBMET00312 | |
| 0.093 | 0.218 | 0.181 | Dyrk kinase inhibitor | 0.181 0.11 DBMET00312 0.163 0.124 DBMET00822 0.163 0.124 DBMET00928 | DBMET00312 | |
| 0.157 | 0.288 | 0.269 | Antibacterial | 0.269 0.16 DBMET00822 0.269 0.16 DBMET00928 | DBMET00928 | |
| 0.072 | 0.204 | 0.123 | Protein kinase (CK1) gamma 1 inhibitor | 0.123 0.095 DBMET00822 0.123 0.095 DBMET00928 | DBMET00928 | |
| 0.118 | 0.25 | 0.299 | Superoxide dismutase inhibitor | 0.299 0.051 DBMET00822 0.299 0.051 DBMET00928 | DBMET00928 | |
| 0.056 | 0.189 | 0.105 | Histone deacetylase class III inhibitor | 0.105 0.084 DBMET00822 0.096 0.094 DBMET00825 0.105 0.084 DBMET00928 | DBMET00928 | |
| 0.129 | 0.263 | 0.254 | Peptidyltransferase inhibitor | 0.165 0.157 DBMET00312 0.254 0.048 DBMET00822 0.242 0.057 DBMET00825 0.163 0.162 DBMET01627 0.254 0.048 DBMET00928 | DBMET00928 | |
| 0.054 | 0.188 | 0.116 | GABA C receptor rho-1 antagonist | 0.116 0.044 DBMET00822 0.116 0.044 DBMET00928 | DBMET00928 | |
| 0.052 | 0.195 | 0.169 | Estrogen receptor beta antagonist | 0.169 0.013 DBMET00312 | DBMET00312 | |
| 0.082 | 0.226 | 0.179 | Dual specificity tyrosine-phosphorylation regulated kinase 1A inhibitor | 0.179 0.106 DBMET00312 0.14 0.139 DBMET00822 0.14 0.139 DBMET00928 | DBMET00312 | |
| 0.027 | 0.176 | 0.163 | Protein kinase (CaMK, MLCK, PhK, SNF, KIN, NIM1, MAPKAP, POLO, CHK, ULK, RSK-2nd domain) inhibitor | 0.163 0.017 DBMET00815 | DBMET00815 | |
| 0.07 | 0.22 | 0.149 | Dual specificity tyrosine-phosphorylation regulated kinase 3 inhibitor | 0.149 0.121 DBMET00822 0.149 0.121 DBMET00928 | DBMET00928 | |
| 0.034 | 0.198 | 0.142 | Protein kinase B gamma inhibitor | 0.142 0.018 DBMET00822 0.142 0.018 DBMET00928 | DBMET00928 | |
| 0.044 | 0.213 | 0.142 | GABA C receptor agonist | 0.142 0.037 DBMET00822 0.142 0.037 DBMET00928 | DBMET00928 | |
| 0.111 | 0.298 | 0.174 | Transcription factor STAT3 inhibitor | 0.174 0.173 DBMET00822 0.174 0.173 DBMET00928 | DBMET00928 | |
| 0.008 | 0.195 | 0.08 | Estrogen agonist | 0.08 0.023 DBMET00312 | DBMET00312 | |
| 0.045 | 0.242 | 0.095 | DNA directed RNA polymerase inhibitor | 0.095 0.062 DBMET00815 | DBMET00815 | |
| 0.036 | 0.235 | 0.07 | Glycine receptor agonist | 0.07 0.054 DBMET00822 0.07 0.054 DBMET00928 | DBMET00928 | |
| 0.009 | 0.209 | 0.09 | Beta tubulin antagonist | 0.09 0.025 DBMET01627 | DBMET01627 | |
| 0.096 | 0.299 | 0.19 | Lipoxygenase inhibitor | 0.19 0.151 DBMET00312 | DBMET00312 | |
| 0.058 | 0.273 | 0.139 | Histone deacetylase SIRT1 inhibitor | 0.139 0.072 DBMET00822 0.128 0.083 DBMET00825 0.139 0.072 DBMET00928 | DBMET00928 | |
| 0.017 | 0.238 | 0.052 | H+/K+-transporting ATPase inhibitor | 0.052 0.034 DBMET01627 | DBMET01627 | |
| 0.069 | 0.299 | 0.138 | Interleukin 6 antagonist | 0.138 0.11 DBMET01627 | DBMET01627 | |
| 0.063 | 0.299 | 0.204 | Interleukin antagonist | 0.204 0.082 DBMET00822 0.191 0.089 DBMET01627 0.204 0.082 DBMET00928 | DBMET00928 | |
| 0.006 | 0.242 | 0.027 | Carnitine palmitoyltransferase 1A inhibitor | 0.027 0.023 DBMET01627 | DBMET01627 | |
| 0.012 | 0.258 | 0.048 | Somatostatin 5 agonist | 0.048 0.013 DBMET00822 0.048 0.013 DBMET00928 | DBMET00928 | |
| 0.004 | 0.278 | 0.029 | Estrogen receptor beta agonist | 0.029 0.024 DBMET00312 | DBMET00312 | |
| 0.033 | 0.31 | 0.128 | Dual specificity tyrosine-phosphorylation-regulated kinase 4 inhibitor | 0.128 0.094 DBMET00822 0.128 0.094 DBMET00928 | DBMET00928 | |
| 0.063 | 0.351 | 0.222 | Tumour necrosis factor alpha release inhibitor | 0.222 0.091 DBMET01627 | DBMET01627 | |
| 0.055 | 0.355 | 0.186 | Free radical scavenger | 0.186 0.109 DBMET00312 | DBMET00312 | |
| 0.008 | 0.367 | 0.034 | Somatostatin 1 antagonist | 0.034 0.031 DBMET00822 0.034 0.031 DBMET00928 | DBMET00928 | |
| 0.035 | 0.497 | 0.161 | Antioxidant | 0.161 0.152 DBMET00312 | DBMET00312 | |
| 0.034 | 0.507 | 0.126 | Toll-Like receptor 3 antagonist | 0.126 0.025 DBMET00825 | DBMET00825 | |
| 0.054 | 0.578 | 0.16 | Death-associated protein kinase 2 inhibitor | 0.16 0.084 DBMET00822 0.16 0.084 DBMET00928 | DBMET00928 | |
| 0.067 | 0.687 | 0.276 | Interleukin 2 agonist | 0.276 0.092 DBMET00822 0.276 0.092 DBMET00928 | DBMET00928 | |
| 0.022 | 0.664 | 0.187 | Interleukin 1b antagonist | 0.187 0.023 DBMET01627 | DBMET01627 | |
| 0.071 | 0.81 | 0.44 | Calcium channel L-type activator | 0.44 0.056 DBMET00825 | DBMET00825 | |
| 0.011 | 0.785 | 0.069 | Somatostatin 1 agonist | 0.069 0.067 DBMET00822 0.069 0.067 DBMET00928 | DBMET00928 | |
| 0.026 | 0.904 | 0.132 | Growth hormone agonist | 0.132 0.104 DBMET00822 0.132 0.104 DBMET00928 | DBMET00928 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |